Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol

INTRODUCTION: The undiminished need for more effective cancer treatments stimulates the development of novel cancer immunotherapy candidates. The archetypical cancer immunotherapy would induce robust, targeted and long-lasting immune responses while simultaneously circumventing immunosuppression in...

Descripción completa

Detalles Bibliográficos
Autores principales: Creemers, Jeroen H A, Pawlitzky, Inka, Grosios, Konstantina, Gileadi, Uzi, Middleton, Mark R, Gerritsen, Winald R, Mehra, Niven, Rivoltini, Licia, Walters, Ian, Figdor, Carl G, Ottevanger, Petronella B, de Vries, I Jolanda M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634237/
https://www.ncbi.nlm.nih.gov/pubmed/34848513
http://dx.doi.org/10.1136/bmjopen-2021-050725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634237/
https://www.ncbi.nlm.nih.gov/pubmed/34848513
http://dx.doi.org/10.1136/bmjopen-2021-050725

Ejemplares similares